US-based Cordance Medical has announced a seed funding round that exceeded its $8m goal, with the proceeds directed to support a focused ultrasound platform trial.
The platform is tailored for temporarily opening the blood-brain barrier (BBB).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Sonder Capital spearheaded the oversubscribed funding round, with participation from both new and current investors, including Shanda Grab Ventures, Angel Physician’s Fund, R42 and SmartGateVC.
The Sontag Foundation Innovation Fund and the Brain Tumor Investment Fund, a venture arm of the National Brain Tumor Society, also took part in the round.
Cordance’s platform is designed for outpatient settings, using patient-specific signal processing and monitoring of BBB opening in real-time. It does not need head fixation or live imaging during procedures.
The company has received a breakthrough device designation from the US Food and Drug Administration (FDA) in neuro-oncology.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIt recently secured a grant from the National Cancer Institute at the National Institutes of Health (NIH) to support its upcoming trial in the US.
Cordance Medical CEO and co-founder Bhaskar Ramamurthy said: “Our team is thrilled to announce this financing round and is grateful to all our investors for their confidence in our mission.
“Alongside our academic collaborators and industry partners, this strong syndicate backing reflects the urgent need for precision therapies in neurology, where patients face extremely limited treatment options. Combined with NIH support for our first-in-human trial, this funding accelerates our path to delivering transformative care.”
In January 2025, Cordance and Abyssinia Biosciences agreed to explore focused ultrasound applications for Alzheimer’s disease diagnosis and treatment.
This partnership focused on the use of Cordance’s SonoBiopsy technology to support early identification of toxic amyloid abnormalities in neurodegenerative disorders.
